Evidence map›Paper›PMID 28736298›Full record

ArticleThe Journal of steroid biochemistry and molecular biology2018

Calcitriol-mediated reduction in IFN-γ output in T cell large granular lymphocytic leukemia requires vitamin D receptor upregulation.

Paige M Kulling, Kristine C Olson, Thomas L Olson, Cait E Hamele, Kathryn N Carter, David J Feith, Thomas P Loughran

Abstract read
In one paragraph

Article in The Journal of steroid biochemistry and molecular biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Paige M KullingUniversity of Virginia Cancer Center, University of Virginia, Charlottesville, VA, 29908, USA; Department of Medicine, Division of Hematology/Oncology, University of Virginia, Charlottesville, VA, 29908, USA; Department of Pathology, University of Virginia, Charlottesville, VA, 29908, USA.
Kristine C OlsonUniversity of Virginia Cancer Center, University of Virginia, Charlottesville, VA, 29908, USA; Department of Medicine, Division of Hematology/Oncology, University of Virginia, Charlottesville, VA, 29908, USA.
Thomas L OlsonUniversity of Virginia Cancer Center, University of Virginia, Charlottesville, VA, 29908, USA; Department of Medicine, Division of Hematology/Oncology, University of Virginia, Charlottesville, VA, 29908, USA.
Cait E HameleUniversity of Virginia Cancer Center, University of Virginia, Charlottesville, VA, 29908, USA; Department of Medicine, Division of Hematology/Oncology, University of Virginia, Charlottesville, VA, 29908, USA.
Kathryn N CarterUniversity of Virginia Cancer Center, University of Virginia, Charlottesville, VA, 29908, USA; Department of Medicine, Division of Hematology/Oncology, University of Virginia, Charlottesville, VA, 29908, USA.
David J FeithUniversity of Virginia Cancer Center, University of Virginia, Charlottesville, VA, 29908, USA; Department of Medicine, Division of Hematology/Oncology, University of Virginia, Charlottesville, VA, 29908, USA.
Thomas P LoughranUniversity of Virginia Cancer Center, University of Virginia, Charlottesville, VA, 29908, USA; Department of Medicine, Division of Hematology/Oncology, University of Virginia, Charlottesville, VA, 29908, USA. Electronic address: tl7cs@virginia.edu.
University of Virginia · USUniversity of Virginia Cancer Center

Funding

Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Dina Gould Halme · 1987 to 2026
$72.1M
Cancer Research Training Program: From Molecular Mechanisms to Therapeutic StrategiesT32CA009109 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Andrew Carl Dudley, Melanie R Rutkowski · 1985 to 2026
$13.9M
INTERDISCIPLINARY TRAINING PROGRAM IN IMMUNOLOGYT32AI007496 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Michael G. Brown, Coleen A McNamara · 1995 to 2026
$10.2M
Survival Mechanisms in Leukemic NK CellsR01CA098472 · NCI · UNIVERSITY OF VIRGINIA · PI LOUGHRAN, THOMAS P. · 2003 to 2016
$4.0M
NCI NIH HHS P30 CA044579NCI NIH HHS R01 CA098472NCI NIH HHS T32 CA009109NIAID NIH HHS T32 AI007496
6 · The paper itself

Abstract

Constitutively activated STAT1 and elevated IFN-γ are both characteristic of T cell large granular lymphocytic leukemia (T-LGLL), a rare incurable leukemia with clonal expansion of cytotoxic T cells due to defective apoptosis. Interferon gamma (IFN-γ) is an inflammatory cytokine that correlates with worse progression and symptomology in multiple autoimmune diseases and cancers. In canonical IFN-γ-STAT1 signaling, IFN-γ activates STAT1, a transcription factor, via phosphorylation of tyrosine residue 701 (p-STAT1). p-STAT1 then promotes transcription of IFN-γ, creating a positive feedback loop. We previously found that calcitriol treatment of the TL-1 cell line, a model of T-LGLL, significantly decreased IFN-γ secretion and p-STAT1 while increasing the vitamin D receptor (VDR) protein. Here we further explore these observations. Using TL-1 cells, IFN-γ decreased starting at 4h following calcitriol treatment, with a reduction in the intracellular and secreted protein levels as well as the mRNA content. A similar reduction in IFN-γ transcript levels was observed in primary T-LGLL patient peripheral blood mononuclear cells (PBMCs). p-STAT1 inhibition followed a similar temporal pattern and VDR upregulation inversely correlated with IFN-γ levels. Using EB1089 and 25(OH)D

Indexed as

AdultAgedCalcitriolCell Line, TumorFemaleHumansInterferon-gammaLeukemia, Large Granular LymphocyticLeukocytes, MononuclearMaleMiddle AgedReceptors, CalcitriolUp-RegulationCalcitriolInterferon-gammaReceptors, CalcitriolCytokinesIFN-gammaLarge granular lymphocytic leukemiaSTAT1Transcription factorsType II interferonVitamin DVitamin D receptor

Identifiers

PMID28736298
PMCPMC5775933
OpenAlexW2737172646

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.